- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03869671
Pre-exposure Prophylaxis (PrEP) for People Who Inject Drugs (PWID)
Optimizing Bio-behavioral HIV Prevention Approaches for People Who Inject Drugs
People who inject drugs (PWID) experience high risk of HIV acquisition. Antiretroviral pre-exposure prophylaxis (PrEP) is an efficacious biomedical HIV prevention strategy for high risk HIV-uninfected individuals including PWID, yet uptake has been low in this population and uptake and adherence interventions have not been developed or tested. Drawing from formative qualitative research, the overall goal of this project is to develop an intervention to promote PrEP uptake and adherence among PWID in the U.S. Northeast. The investigators will:
- Analyze existing literature and data to identify specific barriers and facilitators to PrEP uptake and adherence among PWID to inform the initial adaptation of existing theory-based interventions;
- Conduct qualitative interviews with ~30 PWID and ~10 key informants (PrEP and other clinical and social service providers) to identify intervention targets;
- Develop and iteratively refine and finalize an intervention manual based on feedback from qualitative exit-interviews with an interventionist and ~10 PWID; and
- Conduct a pilot randomized clinical trial (RCT) in ~50 HIV-uninfected PWID to compare PrEP uptake and adherence outcomes and assess intervention feasibility and acceptability.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This mixed methods phased research will use qualitative and quantitative techniques to improve PrEP uptake and adherence among PWID through the following three phases:
- Phase 1 will identify the modifiable determinants of PrEP uptake and adherence among HIV-uninfected PWID using in-depth qualitative interviews with PWID and key informants (KIs). Qualitative interviews will explore perceived acceptability and identify barriers and facilitators to PrEP uptake and adherence among ~30 HIV-uninfected PWID and explore perspectives on optimal PrEP delivery methods with ~15 KIs (e.g., PrEP physicians, community-based organization staff members with experience working with PWID).
- Phase 2 will involve identifying intervention targets and adapting existing intervention strategies to improve PrEP uptake and adherence among PWID. This will involve reviewing the literature to identify and select components of existing, evidence-based medication adherence interventions to adapt for the unique determinants of PrEP uptake and adherence among PWID. Investigators will then develop and iteratively refine and finalize an intervention manual by conducting an open-pilot of the intervention in a community-based setting. Refinements will be based on feedback from qualitative exit-interviews with the interventionist and ~10 PWID.
- Phase 3 will involve pilot testing the resulting PrEP uptake and adherence intervention in a selected community-based setting to obtain preliminary data on PrEP uptake and adherence outcomes (primary outcomes) and intervention feasibility and acceptability (secondary outcomes). Investigators will use a pilot RCT design with a mixed methods process evaluation in which 50 HIV-uninfected PWID will be randomized to the PrEP intervention or a control condition (SEP standard of care; n=25 per arm). Investigators will assess changes in PrEP outcomes (primary outcomes of uptake and adherence) and key implementation measures (e.g., secondary outcomes of acceptability, feasibility, adoption by the interventionist).
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
For all phases:
Inclusion Criteria:
- An adult PWID
- Self report of any high risk behaviors for HIV (past-month receptive syringe sharing, transactional sex, condomless sex with an HIV-infected or unknown status partner)
Exclusion Criteria:
- Unable or unwilling to provide informed consent
For Phase 3 (the RCT pilot):
Inclusion Criteria:
- Clinically eligible for PrEP (confirmed HIV-uninfected status, adequate renal function [estimated creatinine clearance ≥60 ml/min], and documented hepatitis B virus [HBV] status)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: PrEP uptake/adherence intervention
A trained interventionist will deliver the manualized, single session PrEP uptake/adherence intervention in private counseling rooms at a community-based setting.
|
The interventionist will follow the manual to deliver informational and motivational strategies to participants to enhance their PrEP uptake (including completing clinical screening and obtaining/filling a PrEP prescription) and adherence (taking daily oral PrEP doses).
The interventionist will assist participants in problem-solving around topics including limited transportation options, identifying local pharmacies, storing medications given complex living arrangements, coping with side effects, communicating with providers and pharmacists, and maintaining daily medication schedules with reminders and cues.
|
Active Comparator: Harm reduction standard of care
Participants will be provided harm reduction supplies and health information and counseling according to routine practice at the community-based setting.
|
Participants will be provided with harm reduction supplies and health information and counseling according to routine practice at the community-based setting (harm reduction organization).
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PrEP uptake by self-report
Time Frame: 1 month
|
measured using 1 item in a structured questionnaire
|
1 month
|
PrEP uptake by self-report
Time Frame: 3 months
|
measured using 1 item in a structured questionnaire
|
3 months
|
PrEP uptake by pharmacy records
Time Frame: 1 month
|
measured by accessing pharmacy records
|
1 month
|
PrEP uptake by pharmacy records
Time Frame: 3 months
|
measured by accessing pharmacy records
|
3 months
|
PrEP adherence by self-report
Time Frame: 1 month
|
measured using 1 item in a structured questionnaire to determine the proportion of doses taken as prescribed
|
1 month
|
PrEP adherence by self-report
Time Frame: 3 months
|
measured using 1 item in a structured questionnaire to determine the proportion of doses taken as prescribed
|
3 months
|
PrEP adherence by dried blood spot
Time Frame: 1 month
|
measured via detection of tenofovir and emtricitabine in dried blood spots (DBS)
|
1 month
|
PrEP adherence by dried blood spot
Time Frame: 3 months
|
measured via detection of tenofovir and emtricitabine in dried blood spots (DBS)
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Participant satisfaction with intervention content
Time Frame: 1 month
|
assessed via qualitative exit interviews exploring satisfaction with the intervention content (including an open-ended question on topics that were helpful and unhelpful)
|
1 month
|
Participant satisfaction with intervention delivery methods
Time Frame: 1 month
|
assessed via qualitative exit interviews exploring satisfaction with the intervention delivery methods (including an open-ended question on how helpful or unhelpful the intervention delivery methods were)
|
1 month
|
Interventionist satisfaction with training materials
Time Frame: 1 month
|
assessed via qualitative exit interviews exploring satisfaction with the training materials for interventionists (including an open-ended question on how helpful or unhelpful the training materials were)
|
1 month
|
Interventionist satisfaction with intervention manual
Time Frame: 1 month
|
assessed via qualitative exit interviews exploring satisfaction with the intervention manual (including an open-ended question on how helpful or unhelpful the intervention manual was)
|
1 month
|
Interventionist satisfaction with intervention content
Time Frame: 1 month
|
assessed via qualitative exit interviews exploring satisfaction with the intervention content (including an open-ended question on topics that were helpful and unhelpful)
|
1 month
|
Interventionist satisfaction with intervention delivery methods
Time Frame: 1 month
|
assessed via qualitative exit interviews exploring satisfaction with the training materials, intervention manual, intervention content, intervention delivery methods (including an open-ended question on how helpful or unhelpful the intervention delivery methods were)
|
1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Angela Bazzi, PhD, MPH, Boston University
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- H-34960
- K01DA043412-01A1 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Intravenous Drug Abuse
-
Lund UniversityCompletedIntravenous Drug Abuse, S Aureus Colonization
-
Hasselt UniversityZiekenhuis Oost-Limburg; CAD LimburgCompleted
-
State University of New York at BuffaloHellenic Scientific Society for the Study of AIDS, Sexually Transmitted and...CompletedTelemedicine | Social Media | Drug Abuse, Intravenous | InternetGreece
-
Vinay BadhwarEnrolling by invitation
-
University of Northern ColoradoUniversity of Colorado, Denver; Butler HospitalCompletedIntravenous Drug Abuse | HIV InfectionsUnited States
-
Macfarlane Burnet Institute for Medical Research...St Vincent's Hospital MelbourneUnknownHepatitis C | Drug Abuse, IntravenousAustralia
-
Tampere University HospitalDeaconess Foundation; A-Clinic FoundationRecruitingSoft Tissue Injuries | Substance Dependence | Foreign Bodies | Drug Abuse, Intravenous | Needle InjuryFinland
-
Yale UniversityNational Institute on Drug Abuse (NIDA)CompletedChild Abuse | Parent-Child Relations | Parenting | Parents | Addiction | Child Neglect | Substance Abuse Drug Chronic | Child Neglect Emotional | Parent-Child Problem | Parent / Child Problem | Parenteral Drug AbuseUnited States
-
Rockefeller UniversityCompletedIntravenous Drug UsageUnited States
-
South Valley UniversityTanta UniversityCompletedIntravenous Drug UsageEgypt
Clinical Trials on PrEP uptake/adherence intervention
-
University of Massachusetts, WorcesterEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsRecruitingPre-Exposure ProphylaxisThailand
-
Columbia UniversityNational Institute of Mental Health (NIMH); Gilead SciencesCompleted
-
Brown UniversityNational Institute of Mental Health (NIMH); University of Mississippi Medical...CompletedHIV Infections | Preventive MedicineUnited States
-
University of Massachusetts, WorcesterNational Institute of Mental Health (NIMH); Wayne State University; Institute...RecruitingPre-Exposure ProphylaxisThailand
-
Rhode Island HospitalWithdrawnMedication Adherence | Telemedicine | Pre-Exposure ProphylaxisUnited States
-
University of WashingtonKenyatta National Hospital; Fogarty International Center of the National Institute...Active, not recruitingPrEP Uptake | HIV Antibody PositivityKenya
-
Hunter College of City University of New YorkNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Gilead SciencesCompletedHuman Immunodeficiency Virus (HIV)United States
-
Environment and Health Group, Inc.Completed
-
University of MiamiCompleted
-
Duke UniversityChulalongkorn University; Thai Red Cross AIDS Research Centre; University of...CompletedHIV/AIDS | Adherence, Patient | Pre-Exposure ProphylaxisThailand